KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Other Non Operating Income (2019 - 2025)

Historic Other Non Operating Income for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to -$1.6 million.

  • Royalty Pharma's Other Non Operating Income rose 477.63% to -$1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.4 million, marking a year-over-year increase of 5257.55%. This contributed to the annual value of -$1.5 million for FY2024, which is 9297.05% up from last year.
  • Per Royalty Pharma's latest filing, its Other Non Operating Income stood at -$1.6 million for Q3 2025, which was up 477.63% from -$1.5 million recorded in Q2 2025.
  • In the past 5 years, Royalty Pharma's Other Non Operating Income registered a high of $6.0 million during Q2 2024, and its lowest value of -$18.3 million during Q4 2023.
  • In the last 5 years, Royalty Pharma's Other Non Operating Income had a median value of -$1.7 million in 2024 and averaged -$2.6 million.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first tumbled by 418604.65% in 2022, then skyrocketed by 44995.42% in 2024.
  • Quarter analysis of 5 years shows Royalty Pharma's Other Non Operating Income stood at -$4.8 million in 2021, then soared by 75.83% to -$1.2 million in 2022, then crashed by 1471.5% to -$18.3 million in 2023, then soared by 88.04% to -$2.2 million in 2024, then increased by 28.05% to -$1.6 million in 2025.
  • Its last three reported values are -$1.6 million in Q3 2025, -$1.5 million for Q2 2025, and -$3.1 million during Q1 2025.